Investor Relations

The Power of Our Business

InterCure Ltd. (Tel-Aviv Stock Exchange: INCR), ), is disrupting the $42 billion hypertension industry with the world's 1st FDA-cleared, non-drug, non-invasive hypertension treatment device , RESPeRATE®. In a market where 7 out of 10 hypertension patients suffer from inadequately-controlled blood pressure despite the availability of more than 100 blood pressure medications, RESPeRATE offers an affordable option which is clinically proven has no side effects and loved by patients.

InterCure is leading the new trend of device-based hypertension therapies and well on its way to include RESPeRATE as part of the hypertension standard of care. It has spent a decade to amass 10 successful separate clinical studies and 200,000 in-market users prior to reimbursement (paying £200 at Boots, Costco and other retailers)

As of February 1^st, 2012, UK's National Health Service decides to include RESPeRATE as part of the drug tariff making it available at prescription cost in England & Wales. Beyond, the removal of the all-important economic barrier, which prevented masses of patients from trying RESPeRATE, the NHS approval provides the ultimate credibility booster for both the public and the influential medical community.

Beyond hypertension, InterCure has an exciting product pipeline based on its broadly-patented "Device-Guided Respiratory Modulation " technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia, and multiple other medical conditions.

For further information please contact Arik Kleinstein, investors@InterCure.com

Intercure's Highlights

• Large Markets with Unmet Needs
  InterCure's products target some of the most widespread and costly chronic diseases such as hypertension, insomnia and heart failure.
• Significant Medical Breakthrough
  The broadly-patented Device-Guided respiratory modulation platform delivers significant results without side effects, yet is easy to use, natural and non-invasive.
• Cleared Technology, Clinical and Regulatory Hurdles
  Rx & Over-the-counter dual regulatory clearance achieved in the US, Europe and most major markets. Supported by clinical data from 10 studies performed in three continents and published in peer reviewed medical journals.
• Proven Market Demand. A business model that support both out-of-packet and reimbursement
  200,000 RESPeRATE devices have been sold direct-to-consumer prior to reimbursement at £200 (Boots, Costco and directly to patients). UK’s National Health Service reimbursement decision is a game changer.
• Significant Therapeutic Brand in the Making
  A decade of persistent investment in both direct-to-consumer advertising and medical education and created a brand. RESPeRATE's website has already become one of the most trafficked hypertension product destinations and the product is now featured in over in over 20 popular and professional text books including Mayo Clinic's On High Blood Pressure and the American Heart Association's Hypertension Primer.
• Experienced Leadership Team, Scalable Infrastructure in Place
  Led by its founding trio (Chairman, CEO & CSO), in place an scalable infrastructure for developing and commercializing personal therapeutic devices including highly advanced direct marketing capabilities for both consumers and professionals.
• Strong IP Platform
  InterCure has carefully pursued a comprehensive program of intellectual property protection and has received multiple US and international method and device patents. It has received broad patents on a fundamental "method for manipulating biological rhythmic patterns," such as respiration and blood vessel movement.